Mount Sinai has signed an agreement with Clinithink, Ltd. to deploy the CLiX ENRICH system across the organization to accelerate patient recruitment for clinical trials, as well as to support its personalized medicine initiatives. The move followed a successful evaluation of the system at the Icahn School of Medicine at Mount Sinai.
CLiX ENRICH is designed to help streamline the patient prescreening process at Mount Sinai by processing large volumes of progress notes and reports from electronic health records and flagging patients whose clinical documentation indicates they closely match a trial’s inclusion/exclusion criteria. The result is a prioritized shortlist of highly eligible patients.
This will allow investigators to be much quicker in selecting patients to approach for consent and screening. The system eliminates the need for extensive manual chart reviews almost entirely, releasing valuable time traditionally spent by site investigators and coordinators on the laborious task.
A multidisciplinary team of investigators from The Samuel F. Bronfman Department of Medicine, The Charles Bronfman Institute of Personalized Medicine and the Division of Nephrology at The Mount Sinai Hospital recently worked with the Clinithink team to apply CLiX ENRICH to an ongoing diabetic nephropathy trial and evaluate the results.
“Using CLiX ENRICH, we did in a week what would have previously taken four months, so this could represent a paradigm shift in the way clinical trials are carried out for both common as well as rare diseases,” Girish N. Nadkarni, MD, lead investigator for the evaluation, said.
In a second case study, the evaluation team retrospectively applied CLiX ENRICH to a trial in a rare kidney disorder. The team found that the system would have increased trial enrollment by 250 percent and would have found eligible patients in a fraction of the time, according to Mount Sinai.
“This technology is a game changer in the way we will find quality candidates for our clinical trials and will allow us to significantly increase the number of patients to whom we can offer participation in a clinical trial,” Dennis S. Charney, MD, dean of the Icahn School of Medicine at Mount Sinai, said.
